Jean-Luc M. Lemercier - 29 Nov 2021 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP, EMEA, Canada, Latin Amer
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
29 Nov 2021
Net transactions value
-$8,882
Form type
4
Filing time
29 Nov 2021, 19:21:52 UTC
Previous filing
19 May 2021
Next filing
11 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $2,176 +100 +0.07% $21.76 152,203 29 Nov 2021 Direct F1
transaction EW Common Stock Sale $11,058 -100 -0.07% $110.58 152,103 29 Nov 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -100 -0.29% $0.000000 34,880 29 Nov 2021 Common Stock 100 $21.76 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 29, 2021.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This Form 4 includes quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan.